Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ivabradine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,432Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 148849-67-6, Ivabradine hcl, Procoralan, Corlentor, Corlanor, Ivabradine (hydrochloride)
    Molecular Formula
    C27H37ClN2O5
    Molecular Weight
    505.0  g/mol
    InChI Key
    HLUKNZUABFFNQS-ZMBIFBSDSA-N
    FDA UNII
    TP19837BZK
    A benzazepine derivative and selective HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS inhibitor that lowers the heart rate. It is used in the treatment of CHRONIC STABLE ANGINA in patients unable to take BETA-ADRENERGIC BLOCKERS, and in the treatment of HEART FAILURE.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one;hydrochloride
    2.1.2 InChI
    InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1
    2.1.3 InChI Key
    HLUKNZUABFFNQS-ZMBIFBSDSA-N
    2.1.4 Canonical SMILES
    CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC.Cl
    2.1.5 Isomeric SMILES
    CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    TP19837BZK
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one

    2. Corlanor

    3. Ivabradine

    4. S 16257

    5. S 16257 2

    6. S 16257-2

    7. S 162572

    8. S 16260 2

    9. S 16260-2

    10. S 162602

    11. S-16257

    12. S-16257-2

    13. S-16260-2

    14. S16257

    15. S162572

    16. S162602

    2.3.2 Depositor-Supplied Synonyms

    1. 148849-67-6

    2. Ivabradine Hcl

    3. Procoralan

    4. Corlentor

    5. Corlanor

    6. Ivabradine (hydrochloride)

    7. Tp19837bzk

    8. (s)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-benzo[d]azepin-2-one Hydrochloride

    9. Ivabradine Hydrochloride [usan]

    10. Chebi:85969

    11. Amg 998

    12. Amg-998

    13. S-16257-2

    14. 2h-3-benzazepin-2-one, 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-, Hydrochloride (1:1)

    15. Ncgc00181343-01

    16. 148849-67-6 (hcl)

    17. (s)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1h-benzo[d]azepin-2(3h)-one Hydrochloride

    18. 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one Hydrochloride

    19. Ivabradinehydrochloride

    20. Ivabradine Hcl (procoralan)

    21. S16257

    22. Unii-tp19837bzk

    23. Corlentor (tn)

    24. Corlanor (tn)

    25. 2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Hydrochloride (1:1)

    26. 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one Hydrochloride

    27. Coralan (tn)

    28. Ivabrandine Hydrochloride

    29. Ivabradine Monohydrochloride

    30. Dsstox_cid_26913

    31. Dsstox_rid_82011

    32. Dsstox_gsid_46913

    33. Schembl23470

    34. Mls006010110

    35. Ivabradine Hydrochloride- Bio-x

    36. Chembl2145077

    37. Dtxsid2046913

    38. Hy-b0162a

    39. 3-[3-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one;hydrochloride

    40. Bcp05218

    41. Tox21_112802

    42. Ac-543

    43. Ivabradine Hydrochloride (jan/usan)

    44. Ivabradine Hydrochloride [mi]

    45. Mfcd00929899

    46. S2086

    47. Ivabradine Hydrochloride [jan]

    48. Akos015849582

    49. Akos016002249

    50. Bcp9000798

    51. Ccg-269739

    52. Cs-1994

    53. Gs-3584

    54. Ivabradine Hydrochloride [who-dd]

    55. (7,8-dimethoxy 3-(3-(((1s)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one Hydrochloride

    56. (s)-3-(3-(((4,5-dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1h-benzo[d]azepin-2(3h)-one Hydrochloride

    57. Bi164596

    58. Smr004701246

    59. Ivabradine Hydrochloride [ema Epar]

    60. Ivabradine Hydrochloride, >=98% (hplc)

    61. Am20090729

    62. B1360

    63. Cas-148849-67-6

    64. I0847

    65. Ivabradine Hydrochloride [orange Book]

    66. D08095

    67. 974i008

    68. J-008523

    69. J-521616

    70. Q27158823

    71. (+)-s16257

    72. 2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride

    73. 2h-3-benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride, (s)-

    74. 3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one Hydrochloride

    75. 3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Hydrochloride

    76. 3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Hydrochloride3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,

    77. 3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one Hydrochloride

    78. 3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one--hydrogen Chloride (1/1)

    79. N-{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-n-methylpropan-1-aminium Chloride

    2.4 Create Date
    2005-08-09
    3 Chemical and Physical Properties
    Molecular Weight 505.0 g/mol
    Molecular Formula C27H37ClN2O5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count10
    Exact Mass504.2391000 g/mol
    Monoisotopic Mass504.2391000 g/mol
    Topological Polar Surface Area60.5 Ų
    Heavy Atom Count35
    Formal Charge0
    Complexity663
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:

    - in adults unable to tolerate or with a contra-indication to the use of beta-blockers

    or

    - in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

    * Symptomatic treatment of chronic stable angina pectoris:

    Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:

    - in adults unable to tolerate or with a contraindication to the use of beta-blockers

    - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

    * Treatment of chronic heart failure:

    Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

    Symptomatic treatment of chronic stable angina pectoris

    Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:

    - in adults unable to tolerate or with a contraindication to the use of beta-blockers

    - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

    Treatment of chronic heart failure

    Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

    * Symptomatic treatment of chronic stable angina pectoris:

    Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm.

    Ivabradine is indicated:

    - in adults unable to tolerate or with a contra-indication to the use of beta-blockers

    - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

    * Treatment of chronic heart failure:

    Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5. 1)

    Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

    Treatment of angina pectoris, Treatment of chronic heart failure, Treatment of coronary artery disease

    Treatment of angina pectoris, Treatment of chronic heart failure, Treatment of coronary artery disease

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Cardiovascular Agents

    Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)

    5.2 ATC Code

    C01EB17

    C01EB17

    C01EB17

    C01EB17

    C01EB17